Fortune India 500 2025 edition
Rank#275- Total income
- ₹9,600 Cr
- Profit
- ₹91 Cr
Last year #276
Piramal Pharma Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Active Listed - NSE: PPLPHARMA · BSE: 543635 Public Limited Company pharma Fortune India 500 · #275 Nifty 500
Market Cap
₹25,960 Cr
PPLPHARMA · NSE
Share Price
₹190.39
-2.36% today
Revenue
₹8,869 Cr
FY 2025-26 · -3.1% YoY
EBITDA
₹704 Cr
Margin 7.9%
Net Profit
−₹312 Cr
FY 2025-26 · -451.5% YoY
ROE
-3.8%
ROCE 2.5%
Debt / Equity
0.65
Interest cover -267.9x
Authorised capital
₹3,000 Cr
Registered with MCA
About Piramal Pharma Limited
Data last updated:
Piramal Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 04 March 2020 and has been in existence for over 6 years.
Piramal Pharma is ranked #275 on the Fortune India 500 (2025). It is part of the Nifty 500 and BSE 500 indices.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24297MH2020PLC338592. Its GSTIN is 27AALCP0909M1Z1 (Maharashtra). The company holds 19 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 543635 and NSE: PPLPHARMA.
The company has an authorised share capital of ₹3,000 Cr and a paid-up capital of ₹1,331.35 Cr. It is led by directors including Peter D Deyoung (Whole-Time Director) and Nandini Ajay Piramal (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 July 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Ananta Building Piramal Corporate Park, Mumbai, Maharashtra.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹8,869.08 Cr, a decline of 3.1% compared to the previous year. For the same year it recorded a net loss of ₹312.22 Cr (net margin -3.5%) and EBITDA of ₹704.05 Cr (EBITDA margin 7.9%). The net worth stands at ₹8,162.62 Cr (up 0.5% YoY). Total assets are valued at ₹14,088 Cr (up 6.7% YoY).
The company has about 3,851 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 4 brands: Piramal Pharma Solutions, Piramal Realty, Piramal Pharma and Piramal Group. As per MCA filings, the company has open charges of ₹2,430 Cr and satisfied charges of ₹1,000 Cr on record. Court records list 64 cases involving the company, including 50 filed by the company and 14 filed against it; 32 cases are pending. The company has 10 deals on record (5 market trades, 3 funding rounds, 1 rights issue), with disclosed funding of ₹4,300.42 Cr; the latest was in February 2025. Its 10 peer companies in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is Dow Chemical International Private Limited with revenue of ₹10,135 Cr. The company has 11 MSME Form 1 returns on record between 2021 and 2024, listing 326 overdue payments to 94 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website piramal.com.
Company details
CIN L24297MH2020PLC338592
Registration Number 338592
Incorporation Date 04 March 2020
ROC Mumbai
Listing Status Listed - Listed on NSE (PPLPHARMA); Listed on BSE (543635)
Company Status Active
Date of Last AGM 30 July 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
CIN history
Piramal Pharma has one previous CIN (Corporate Identification Number): U24297MH2020PLC338592. The current CIN is L24297MH2020PLC338592, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24297MH2020PLC338592 | Current |
| U24297MH2020PLC338592 | Previous |
Key People
Peter D Deyoung Whole-Time Director Nandini Ajay Piramal Whole-Time Director Vivek Valsaraj Whole-Time Director Recognitions & Rankings of Piramal Pharma
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#179- Valuation
- ₹33,910 Cr
2023 #332 2022 #196
Stock market indices
Nifty 500 BSE 500
Contact details
Piramal Pharma Limited's registered office is in Mumbai, Maharashtra. Its website is piramal.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressAnanta Building Piramal Corporate Park, Opp. Fire Brigade Kamani Junction Lbs Marg Kurla (West), Mumbai, Maharashtra, India – 400070
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Piramal Pharma Limited, buy the company report.
Comprehensive company report
Piramal Pharma Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Piramal Pharma operates multiple associated brands including Piramal Pharma Solutions, Piramal Realty, and Piramal Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Serves as a contract manufacturer of pharmaceutical products for industry partners. | piramalpharmasolutions.com | |
| Development services for residential, commercial, and mixed-use projects are provided. | piramalrealty.com | |
| Innovative healthcare solutions are delivered through end-to-end manufacturing capabilities. | piramalpharma.com | |
| Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate | piramal.com |
Business activity
The main business activity of Piramal Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Piramal Pharma Limited, buy the company report.
Financials of Piramal Pharma Limited
FY 2025-26 filings availablePiramal Pharma Limited reported revenue of ₹8,869.08 Cr (down 3.1% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹8,869 Cr
-3.1% YoY
EBITDA
₹704 Cr
-51.3% YoY
Profit After Tax
−₹312 Cr
-451.5% YoY
Net Worth
₹8,163 Cr
+0.5% YoY
Total Assets
₹14,088 Cr
+6.7% YoY
Total Debt
₹5,675 Cr
+16.8% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 8,869 | 9,151 | 8,171 | 7,082 | 6,559 | 6,315 |
| Revenue growth | -3.1% | +12.0% | +15.4% | +8.0% | +3.9% | - |
| EBITDA | 704 | 1,445 | 1,133 | 621 | 935 | 1,428 |
| EBITDA margin | +7.9% | +15.8% | +13.9% | +8.8% | +14.3% | +22.6% |
| Profit before tax | (176) | 415 | 179 | (120) | 485 | 949 |
| Net profit | (312) | 88.82 | 15.83 | (186) | 384 | 818 |
| Net profit margin | -3.5% | +1.0% | +0.2% | -2.6% | +5.9% | +13.0% |
| EPS (₹) | (2.46) | 0.69 | 0.13 | (1.56) | 3.17 | 8.40 |
| Balance sheet | ||||||
| Total assets | 14,088 | 13,206 | 12,822 | 12,612 | 10,991 | 8,780 |
| Net worth | 8,163 | 8,125 | 7,911 | 6,774 | 6,697 | 5,605 |
| Total debt | 5,675 | 4,856 | 4,710 | 5,637 | 4,128 | 3,025 |
| Cash & bank | 1,224 | 501 | 483 | 308 | 329 | 406 |
| Net working capital | 3,541 | 3,554 | 3,059 | 2,717 | 2,403 | 1,751 |
| Cash flow | ||||||
| Cash from operations | 1,653 | 892 | 1,005 | 484 | 766 | 598 |
| Cash from investing | (820) | (488) | (416) | (1,334) | (1,737) | (4,464) |
| Cash from financing | (38.98) | (441) | (422) | 818 | 794 | 3,977 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,270 | 2,752 | 2,140 | 2,044 | 1,934 | 2,754 | 2,204 | 2,242 |
| Revenue growth (YoY) | +17.4% | -0.1% | -2.9% | -8.8% | -0.9% | - | - | - |
| Other income | 109 | 59.63 | 53.50 | 80.39 | 97.71 | 58.25 | 29.18 | 78.37 |
| EBITDA | 195 | 285 | 155 | 159 | 107 | 561 | 338 | 342 |
| EBITDA margin | +8.6% | +10.3% | +7.2% | +7.8% | +5.5% | +20.4% | +15.3% | +15.2% |
| Depreciation | 224 | 218 | 213 | 203 | 197 | 243 | 197 | 192 |
| Interest | 88.08 | 82.99 | 89.24 | 82.42 | 86.15 | 104 | 103 | 108 |
| Profit before tax | (7.46) | 43.00 | (93.86) | (46.18) | (79.02) | 273 | 66.80 | 120 |
| Tax | 61.93 | 51.83 | 42.33 | 53.04 | 2.68 | 119 | 63.12 | 97.53 |
| Net profit | (69.39) | (8.83) | (136) | (99.22) | (81.70) | 154 | 3.68 | 22.59 |
| EPS (₹) | (0.52) | (0.07) | (1.03) | (0.75) | (0.62) | 1.16 | 0.03 | 0.17 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 4,782 | 5,286 | 4,390 | 3,443 | 3,340 | 2,939 |
| Revenue growth | -9.5% | +20.4% | +27.5% | +3.1% | +13.7% | - |
| EBITDA | 549 | 1,040 | 618 | 90.57 | 460 | 619 |
| EBITDA margin | +11.5% | +19.7% | +14.1% | +2.6% | +13.8% | +21.1% |
| Profit before tax | 877 | 911 | 508 | 124 | 462 | 687 |
| Net profit | 768 | 689 | 388 | 72.64 | 378 | 556 |
| Net profit margin | +16.1% | +13.0% | +8.8% | +2.1% | +11.3% | +18.9% |
| EPS (₹) | 5.27 | 5.22 | 2.96 | 0.58 | 3.10 | 5.75 |
| Balance sheet | ||||||
| Total assets | 9,022 | 8,744 | 7,921 | 6,936 | 6,300 | 4,281 |
| Net worth | 8,141 | 7,453 | 6,712 | 5,262 | 5,123 | 4,101 |
| Total debt | 786 | 1,243 | 1,177 | 1,649 | 1,164 | 174 |
| Cash & bank | 574 | 178 | 242 | 64.16 | 137 | 152 |
| Net working capital | 1,842 | 2,101 | 1,797 | 1,337 | 1,166 | 463 |
| Cash flow | ||||||
| Cash from operations | 1,328 | 549 | 358 | 71.52 | 249 | 34.72 |
| Cash from investing | (318) | (552) | (635) | (435) | (1,165) | (4,383) |
| Cash from financing | (615) | (61.74) | 451 | 290 | 896 | 4,494 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,125 | 1,489 | 1,196 | 1,127 | 970 | 1,690 | 1,248 | 1,284 |
| Revenue growth (YoY) | +16.0% | -11.9% | -4.2% | -12.2% | -8.8% | - | - | - |
| Other income | 115 | 184 | 96.15 | 202 | 181 | 39.51 | 24.70 | 106 |
| Total expenses | 1,008 | 1,251 | 1,056 | 1,000 | 926 | 1,273 | 1,029 | 1,032 |
| EBITDA | 117 | 238 | 140 | 127 | 44.33 | 417 | 219 | 253 |
| EBITDA margin | +10.4% | +16.0% | +11.7% | +11.3% | +4.6% | +24.7% | +17.6% | +19.7% |
| Depreciation | 65.73 | 70.12 | 64.69 | 61.25 | 59.44 | 61.17 | 55.46 | 53.61 |
| Interest | 16.36 | 19.50 | 16.84 | 20.38 | 23.23 | 30.56 | 29.17 | 29.95 |
| Profit before tax | 149 | 332 | 155 | 247 | 143 | 364 | 159 | 276 |
| Tax | 36.00 | 70.22 | 26.02 | 51.08 | 29.44 | 87.09 | 40.61 | 65.65 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,270 | 2,752 | 2,140 | 2,044 | 1,934 | 2,754 | 2,204 | 2,242 |
| Revenue growth (YoY) | +17.4% | -0.1% | -2.9% | -8.8% | -0.9% | - | - | - |
| Other income | 109 | 59.63 | 53.50 | 80.39 | 97.71 | 58.25 | 29.18 | 78.37 |
| EBITDA | 195 | 285 | 155 | 159 | 107 | 561 | 338 | 342 |
| EBITDA margin | +8.6% | +10.3% | +7.2% | +7.8% | +5.5% | +20.4% | +15.3% | +15.2% |
| Depreciation | 224 | 218 | 213 | 203 | 197 | 243 | 197 | 192 |
| Interest | 88.08 | 82.99 | 89.24 | 82.42 | 86.15 | 104 | 103 | 108 |
| Profit before tax | (7.46) | 43.00 | (93.86) | (46.18) | (79.02) | 273 | 66.80 | 120 |
| Tax | 61.93 | 51.83 | 42.33 | 53.04 | 2.68 | 119 | 63.12 | 97.53 |
| Net profit | (69.39) | (8.83) | (136) | (99.22) | (81.70) | 154 | 3.68 | 22.59 |
| EPS (₹) | (0.52) | (0.07) | (1.03) | (0.75) | (0.62) | 1.16 | 0.03 | 0.17 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 8,869 | 9,151 | 8,171 | 7,082 | 6,559 | 6,315 |
| Revenue growth | -3.1% | +12.0% | +15.4% | +8.0% | +3.9% | - |
| Other income | 292 | 208 | 235 | 279 | 335 | 230 |
| Total expenses | 8,165 | 7,706 | 7,038 | 6,460 | 5,625 | 4,887 |
| Employee cost | 2,416 | 2,307 | 2,030 | 1,896 | 1,589 | 1,468 |
| EBITDA | 704 | 1,445 | 1,133 | 621 | 935 | 1,428 |
| EBITDA margin | +7.9% | +15.8% | +13.9% | +8.8% | +14.3% | +22.6% |
| Depreciation | 831 | 816 | 741 | 677 | 586 | 545 |
| Interest | 341 | 422 | 448 | 344 | 198 | 163 |
| Profit before tax | (176) | 415 | 179 | (120) | 485 | 949 |
| Tax | 150 | 324 | 161 | 66.31 | 109 | 114 |
| Net profit | (312) | 88.82 | 15.83 | (186) | 384 | 818 |
| Net profit margin | -3.5% | +1.0% | +0.2% | -2.6% | +5.9% | +13.0% |
| EPS (₹) | (2.46) | 0.69 | 0.13 | (1.56) | 3.17 | 8.40 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 1,327 | 1,324 | 1,323 | 1,193 | 1,186 | 995 |
| Reserves & surplus | 6,835 | 6,801 | 6,588 | 5,580 | 5,511 | 4,610 |
| Shareholders' funds (net worth) | 8,163 | 8,125 | 7,911 | 6,774 | 6,697 | 5,605 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 5,470 | 4,590 | 4,536 | 5,497 | 3,981 | 2,601 |
| Unsecured loans | 204 | 266 | 174 | 140 | 146 | 424 |
| Total debt | 5,675 | 4,856 | 4,710 | 5,637 | 4,128 | 3,025 |
| Total liabilities | 14,088 | 13,206 | 12,822 | 12,612 | 10,991 | 8,780 |
| Assets | ||||||
| Gross block | 14,829 | 13,077 | 12,099 | 10,842 | 9,510 | 8,153 |
| Net block | 8,684 | 8,133 | 7,990 | 7,469 | 6,879 | 6,105 |
| Capital work in progress | 1,100 | 977 | 1,116 | 1,419 | 1,172 | 627 |
| Investments | 437 | 291 | 385 | 639 | 267 | 123 |
| Inventories | 3,064 | 2,313 | 2,176 | 1,681 | 1,389 | 1,232 |
| Sundry debtors | 2,158 | 2,350 | 2,134 | 1,799 | 1,785 | 1,575 |
| Cash & bank balances | 1,224 | 501 | 483 | 308 | 329 | 406 |
| Loans & advances | 614 | 614 | 527 | 620 | 514 | 436 |
| Total current assets | 7,060 | 5,777 | 5,320 | 4,408 | 4,017 | 3,649 |
| Total current liabilities | 3,519 | 2,223 | 2,261 | 1,691 | 1,614 | 1,898 |
| Net working capital | 3,541 | 3,554 | 3,059 | 2,717 | 2,403 | 1,751 |
| Total assets | 14,088 | 13,206 | 12,822 | 12,612 | 10,991 | 8,780 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 182 | 219 | 53.23 | 85.18 | 262 | 152 |
| Net cash from operating activities | 1,653 | 892 | 1,005 | 484 | 766 | 598 |
| Net cash from investing activities | (820) | (488) | (416) | (1,334) | (1,737) | (4,464) |
| Net cash from financing activities | (38.98) | (441) | (422) | 818 | 794 | 3,977 |
| Net change in cash | 794 | (36.87) | 166 | (31.95) | (177) | 110 |
| Closing cash | 1,224 | 501 | 483 | 308 | 329 | 406 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | -3.1% | +12.0% | +15.4% | +8.0% | +3.9% | - |
| EBITDA growth | -51.3% | +27.5% | +82.4% | -33.5% | -34.6% | - |
| PBT growth | - | +131.3% | +9998.0% | - | -48.9% | +9997.0% |
| Net income growth | -451.5% | +461.1% | +108.5% | -148.4% | -53.0% | - |
| Revenue CAGR (3Y) | +7.8% | +11.7% | +9.0% | - | - | - |
| EBITDA CAGR (3Y) | +4.3% | +15.6% | -7.4% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | -3.7% | +1.0% | +0.2% | -2.6% | +5.7% | +13.2% |
| Return on capital employed | +2.5% | +6.4% | +5.4% | +1.9% | +6.9% | +12.7% |
| Return on net worth | -3.8% | +1.1% | +0.2% | -2.8% | +6.1% | +14.9% |
| Debt / equity | 0.65 | 0.60 | 0.70 | 0.72 | 0.58 | 0.54 |
| Long-term debt / equity | 0.48 | 0.37 | 0.41 | 0.46 | 0.42 | 0.43 |
| Interest cover | -267.95 | 67.08 | 114.15 | -621.15 | 56.90 | 18.51 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 0.64 | 0.73 | 0.71 | 0.70 | 0.74 | 0.77 |
| Inventory turnover | 3.30 | 4.08 | 4.24 | 4.61 | 5.01 | 5.13 |
| Debtors turnover | 3.94 | 4.08 | 4.15 | 3.95 | 3.90 | 4.01 |
| EPS (₹) | (2.46) | 0.69 | 0.13 | (1.56) | 3.17 | 8.40 |
| Dividend per share (₹) | 0.00 | 0.14 | 0.11 | 0.00 | 0.56 | 0.00 |
| Book value per share (₹) | 61.50 | 61.35 | 59.80 | 56.76 | 56.47 | 56.35 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,125 | 1,489 | 1,196 | 1,127 | 970 | 1,690 | 1,248 | 1,284 |
| Revenue growth (YoY) | +16.0% | -11.9% | -4.2% | -12.2% | -8.8% | - | - | - |
| Other income | 115 | 184 | 96.15 | 202 | 181 | 39.51 | 24.70 | 106 |
| Total expenses | 1,008 | 1,251 | 1,056 | 1,000 | 926 | 1,273 | 1,029 | 1,032 |
| EBITDA | 117 | 238 | 140 | 127 | 44.33 | 417 | 219 | 253 |
| EBITDA margin | +10.4% | +16.0% | +11.7% | +11.3% | +4.6% | +24.7% | +17.6% | +19.7% |
| Depreciation | 65.73 | 70.12 | 64.69 | 61.25 | 59.44 | 61.17 | 55.46 | 53.61 |
| Interest | 16.36 | 19.50 | 16.84 | 20.38 | 23.23 | 30.56 | 29.17 | 29.95 |
| Profit before tax | 149 | 332 | 155 | 247 | 143 | 364 | 159 | 276 |
| Tax | 36.00 | 70.22 | 26.02 | 51.08 | 29.44 | 87.09 | 40.61 | 65.65 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 4,782 | 5,286 | 4,390 | 3,443 | 3,340 | 2,939 |
| Revenue growth | -9.5% | +20.4% | +27.5% | +3.1% | +13.7% | - |
| Other income | 663 | 207 | 202 | 341 | 225 | 216 |
| Total expenses | 4,233 | 4,245 | 3,772 | 3,353 | 2,880 | 2,320 |
| Employee cost | 745 | 736 | 614 | 548 | 448 | 395 |
| EBITDA | 549 | 1,040 | 618 | 90.57 | 460 | 619 |
| EBITDA margin | +11.5% | +19.7% | +14.1% | +2.6% | +13.8% | +21.1% |
| Depreciation | 256 | 222 | 205 | 192 | 165 | 144 |
| Interest | 79.95 | 115 | 107 | 116 | 57.29 | 4.71 |
| Profit before tax | 877 | 911 | 508 | 124 | 462 | 687 |
| Tax | 177 | 220 | 116 | 54.19 | 94.79 | 115 |
| Net profit | 768 | 689 | 388 | 72.64 | 378 | 556 |
| Net profit margin | +16.1% | +13.0% | +8.8% | +2.1% | +11.3% | +18.9% |
| EPS (₹) | 5.27 | 5.22 | 2.96 | 0.58 | 3.10 | 5.75 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 1,327 | 1,324 | 1,323 | 1,193 | 1,186 | 995 |
| Reserves & surplus | 6,814 | 6,128 | 5,389 | 4,068 | 3,937 | 3,106 |
| Shareholders' funds (net worth) | 8,141 | 7,453 | 6,712 | 5,262 | 5,123 | 4,101 |
| Secured loans | 421 | 1,009 | 896 | 1,313 | 1,154 | 90.20 |
| Unsecured loans | 365 | 234 | 281 | 336 | 10.69 | 84.06 |
| Total debt | 786 | 1,243 | 1,177 | 1,649 | 1,164 | 174 |
| Total liabilities | 9,022 | 8,744 | 7,921 | 6,936 | 6,300 | 4,281 |
| Assets | ||||||
| Gross block | 4,575 | 4,249 | 3,767 | 3,565 | 3,225 | 2,260 |
| Net block | 3,036 | 2,894 | 2,612 | 2,602 | 2,439 | 1,627 |
| Capital work in progress | 221 | 327 | 533 | 417 | 405 | 121 |
| Investments | 3,580 | 3,105 | 1,708 | 1,747 | 1,630 | 1,592 |
| Inventories | 1,873 | 1,205 | 1,153 | 819 | 536 | 421 |
| Sundry debtors | 1,406 | 1,667 | 1,331 | 910 | 989 | 840 |
| Cash & bank balances | 574 | 178 | 242 | 64.16 | 137 | 152 |
| Loans & advances | 451 | 486 | 504 | 456 | 403 | 355 |
| Total current assets | 4,305 | 3,536 | 3,230 | 2,249 | 2,065 | 1,768 |
| Total current liabilities | 2,462 | 1,434 | 1,433 | 912 | 899 | 1,305 |
| Net working capital | 1,842 | 2,101 | 1,797 | 1,337 | 1,166 | 463 |
| Total assets | 9,022 | 8,744 | 7,921 | 6,936 | 6,300 | 4,281 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 164 | 229 | 54.28 | 128 | 147 | 0.74 |
| Net cash from operating activities | 1,328 | 549 | 358 | 71.52 | 249 | 34.72 |
| Net cash from investing activities | (318) | (552) | (635) | (435) | (1,165) | (4,383) |
| Net cash from financing activities | (615) | (61.74) | 451 | 290 | 896 | 4,494 |
| Net change in cash | 395 | (64.93) | 175 | (73.41) | (19.03) | 146 |
| Closing cash | 574 | 178 | 242 | 64.16 | 137 | 152 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | -9.5% | +20.4% | +27.5% | +3.1% | +13.7% | - |
| EBITDA growth | -47.2% | +68.4% | +582.3% | -80.3% | -25.7% | - |
| PBT growth | -3.8% | +79.5% | +310.4% | -73.3% | -32.7% | +9997.0% |
| Net income growth | +11.4% | +77.6% | +434.0% | -80.8% | -32.0% | - |
| Revenue CAGR (3Y) | +11.6% | +16.5% | +14.3% | - | - | - |
| EBITDA CAGR (3Y) | +82.4% | +31.3% | -0.1% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +14.6% | +13.1% | +8.9% | +2.0% | +11.0% | +19.5% |
| Return on capital employed | +10.8% | +12.3% | +8.3% | +3.6% | +9.8% | +16.2% |
| Return on net worth | +9.0% | +9.8% | +6.5% | +1.3% | +8.0% | +13.9% |
| Debt / equity | 0.13 | 0.17 | 0.24 | 0.27 | 0.15 | 0.04 |
| Long-term debt / equity | 0.05 | 0.05 | 0.08 | 0.11 | 0.05 | 0.00 |
| Interest cover | 27.19 | 14.00 | 25.95 | -114.15 | 19.43 | 0.99 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 1.08 | 1.32 | 1.20 | 1.01 | 1.22 | 1.30 |
| Inventory turnover | 3.11 | 4.48 | 4.45 | 5.09 | 6.99 | 6.98 |
| Debtors turnover | 3.11 | 3.53 | 3.92 | 3.63 | 3.65 | 3.50 |
| EPS (₹) | 5.27 | 5.22 | 2.96 | 0.58 | 3.10 | 5.75 |
| Dividend per share (₹) | 0.00 | 0.14 | 0.11 | 0.00 | 0.56 | 0.00 |
| Book value per share (₹) | 61.34 | 56.27 | 50.74 | 44.09 | 43.20 | 41.23 |
To see the full year-wise statements and ratios of Piramal Pharma Limited, buy the company report.
Board of directors of Piramal Pharma Limited
Piramal Pharma has 10 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Peter D Deyoung | Whole-Time Director | 04 Mar 2020 | 6 Years 7 Months | Current |
| Ramadorai Subramanian Also directs: DSP Asset Managers Private Limited, British Asian India Foundation, Karmayogi Bharat and 3 more | Director | 09 Feb 2021 | 5 Years 8 Months | Current |
| Jairaj Manohar Purandare Also directs: J M Purandare & Co LLP, Cie Automotive India Limited, HDFC Asset Management Company Limited and 3 more | Director | 09 Feb 2021 | 5 Years 8 Months | Current |
| Sridhar Gorthi | Director | 30 Mar 2022 | 4 Years 6 Months | Current |
| Nandini Ajay Piramal | Whole-Time Director | 04 Mar 2020 | 6 Years 7 Months | Current |
| Vivek Valsaraj Also directs: Abbvie Therapeutics India Private Limited | Whole-Time Director | 09 Feb 2022 | 4 Years 8 Months | Current |
Showing 6 of 10 current directors. View all directors
Peer comparison
Piramal Pharma Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Dow Chemical International Private Limited | ₹10,135 Cr (FY 2025) | 4.0% | Thane, Maharashtra, India | |||
| Reckitt Benckiser (India) Private Limited | ₹9,882.29 Cr (FY 2025) | 5.0% | Gurgaon, Haryana, India | |||
| Gujarat State Fertilizers & Chemicals Limited | ₹9,848.64 Cr (FY 2025) | 3.0% | Vadodara, Gujarat, India | |||
| Divi's Laboratories Limited | ₹9,712 Cr (FY 2025) | 19.0% | Hyderabad, Telangana, India | |||
| Macleods Pharmaceuticals Ltd | ₹9,671.68 Cr (FY 2025) | 5.0% | Mumbai, Maharashtra, India | |||
| Procter & Gamble Home Products Private Limited | ₹9,228.83 Cr (FY 2025) | -2.0% | Mumbai, Maharashtra, India | |||
| India Glycols Limited | ₹9,053.5 Cr (FY 2025) | 14.0% | Udham Singh Nagar, Uttarakhand, India | |||
| Ipca Laboratories Limited | ₹9,032.39 Cr (FY 2025) | 15.0% | Mumbai, Maharashtra, India | |||
| Piramal Pharma Limitedthis company | ₹8,869.08 Cr (FY 2026) | -₹312.22 Cr | -3.5% | -3.1% | 3,851 | Mumbai, Maharashtra, India |
| Abbott Healthcare Private Limited | ₹8,811.32 Cr (FY 2025) | 3.0% | Mumbai, Maharashtra, India | |||
| Deccan Fine Chemicals (India) Private Limited | ₹8,738.51 Cr (FY 2024) | -1.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Piramal Pharma Limited, buy the company report.
Auditor
Piramal Pharma Limited is audited by Deloitte Haskins & Sells LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Deloitte Haskins & Sells LLP | FY 2023 | 117366W/W-100018 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 34.80%, foreign institutional investors hold 12.50%, domestic institutional investors hold 14.60% and retail and other public shareholders hold 38.10%.
Sep 2026
QUARTER
34.80% Promoters
14.60% DII (Domestic Institutional)
12.50% FII (Foreign Institutional)
38.10% Retail & Others
Promoter holding - history
Now 34.80% · Sep 2026High 34.90% · Dec 2025Low 34.80% · Sep 2026
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 34.80% | 34.90% | 34.90% | 34.90% |
| Public | 65.20% | 65.10% | 65.10% | 65.10% |
Charges & borrowings
Open charges
₹2,430 Cr
Satisfied charges
₹1,000 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 19 May 2025 | 101100712 | Idbi Trusteeship Services Limited | ₹300 Cr | Open | |
| 12 Dec 2024 | 101026540 | Idbi Trusteeship Services Limited | ₹100 Cr | Open | |
| 10 Dec 2024 | 101019951 | Idbi Trusteeship Services Limited | ₹200 Cr | Open | |
| 10 Dec 2024 | 101022133 | Idbi Trusteeship Services Limited | ₹100 Cr | Open | |
| 10 Sep 2024 | 100977502 | Idbi Trusteeship Services Limited | ₹150 Cr | Open |
To see the full charge records of Piramal Pharma Limited, buy the company report.
Total charge records: 20 View all charges
Deals & funding
Piramal Pharma Limited has 10 deals on record (5 market trades, 3 funding rounds, 1 rights issue), with disclosed funding of ₹4,300.42 Cr; the latest was in February 2025.
Total deals
10
Market trades
5
Funding rounds
3
Rights issue
1
Acquisition
1
Disclosed funding
₹4,300.42 Cr
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Feb 2025 | Market trade | ₹150.77 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Oct 2023 | Market trade | ₹345.85 Cr | Buyer: East Bridge Capital Master Fund I Limited Seller: an individual |
| Aug 2023 | Rights issue | ₹1,050 Cr | Investors: Others - Piramal Pharma Limited, Icici Prudential Value Discovery Fund, 2 individuals |
| Jun 2023 | Market trade | ₹99.87 Cr | Buyer: The Vanguard Group Inc Ac Vanguard Total International Stock Index Fund Seller: an individual |
| Nov 2022 | Market trade | ₹135.25 Cr | Buyer: an individual Seller: Ishares Core Emerging Markets Mauritius Co |
To see the full deal history of Piramal Pharma Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Piramal Pharma Limited has 64 court cases on record: 50 filed by Piramal Pharma, 14 filed against it. 32 cases are pending and 32 are disposed.
Total cases
64
Filed by the company
50
Filed against the company
14
Pending
32
Disposed
32
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 50 | 13 | 31 |
| High courts | 6 | 1 | 1 |
| Supreme Court | 4 | 0 | 0 |
| NCLT | 4 | 0 | 0 |
Cases on record (5 of 64)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai City Civil Court, Maharashtra | Interim or miscellaneous application | Filed by the company against One Solution Advertisers Private Limited | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Court case (SUMMARY) | Filed by the company against Pathways Retail Private Limited and 2 others | Pending |
| District court, Mumbai City Civil Court, Maharashtra | Commercial matter | Filed by the company against One Solution Advertisers Private Limited and 3 others | Pending |
| District court, Mumbai City Civil Court, Maharashtra | Commercial suit | Filed against the company by One Solution Advertisers Pvt. Ltd. | Pending |
| High Court of Gujarat | Special civil application | Filed by the company against Dakshin Gujarat Vij Company Limited and 1 other | Disposed |
To see the full case history of Piramal Pharma Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Piramal Pharma Limited was last rated by Care on 29 Mar 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 29 Mar 2022 |
To see the full credit ratings and regulatory alerts of Piramal Pharma Limited, buy the company report.
MSME payment delays
Piramal Pharma Limited has 11 MSME Form 1 returns on record between 2021 and 2024, listing 326 overdue payments to 94 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 94)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Refer Annexure | |||
| Scientific Research Instruments Company Private Limited | |||
| Sagra Hvac Private Limited | |||
| an individual supplier | |||
| Entex Private Limited |
To see the full MSME payment records of Piramal Pharma Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Piramal Pharma has 1 subsidiary company and 2 associated companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
1
Subsidiary companies
2
Associated companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Piramal Pharma II Private Limited | U24230MH2022PTC384232 |
To see the full group structure of Piramal Pharma Limited, buy the company report.
Employees & EPFO
Piramal Pharma Limited has a workforce of 3,851 employees on its EPFO records as of Apr 02, 2024, across 5 active EPFO establishments.
Employee count
3,851
Active EPFO establishments
5
Employee growth
2.97%
GST
Piramal Pharma has 19 GST registrations: 19 active. The first 4 active GSTINs are listed below.
Total GSTINs
19
Active
19
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AALCP0909M1Z1 | Maharashtra | Active | 21 Jul 2020 |
| 27AALCP0909M2Z0 | Maharashtra | Active | 28 Jul 2020 |
| 36AALCP0909M1Z2 | Telangana | Active | 21 Jul 2020 |
| 23AALCP0909M1Z9 | Madhya Pradesh | Active | 23 Jul 2020 |
To see the full GST registrations and return filing status of Piramal Pharma Limited, buy the company report.
Recent activity
Piramal Pharma Limited has 14 board changes on record since 2020: 12 appointments and 2 cessations. The latest: Amit Jain was appointed as Director on 14 May 2025.
Filing
Piramal Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
AGM
Piramal Pharma Limited last Annual general meeting of members was held on 30 Jul 2025 as per latest MCA records.
Charges
A charge with Idbi Trusteeship Services Limited amounted to Rs. 300.00 Cr with Charge ID 101100712 was registered on 19 May 2025.
Appointed
Amit Jain was appointed as Director.
Ceased
Neeraj Bharadwaj ceased to be Director.
Appointed
Nathalie Ann Leitch was appointed as Director.
Charges
A charge with Idbi Trusteeship Services Limited amounted to Rs. 100.00 Cr with Charge ID 101026540 was registered on 12 Dec 2024.
Charges
A charge with Idbi Trusteeship Services Limited amounted to Rs. 200.00 Cr with Charge ID 101019951 was registered on 10 Dec 2024.
Charges
A charge with Idbi Trusteeship Services Limited amounted to Rs. 100.00 Cr with Charge ID 101022133 was registered on 10 Dec 2024.
Charges
A charge with Others of Rs. 200.00 Cr registered on 23 Aug 2021 with Charge ID 100476536 was modified on 19 Sep 2024.
Charges
A charge with Idbi Trusteeship Services Limited amounted to Rs. 150.00 Cr with Charge ID 100977502 was registered on 10 Sep 2024.
Charges
A charge registered on 04 Jan 2022 via Charge ID 100528888 with Idbi Trusteeship Services Limited was fully satisfied on 06 May 2024.
33 earlier events are in the company report.
News
Frequently asked questions
Piramal Pharma is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 04 March 2020 (6+ years old) and is registered under CIN L24297MH2020PLC338592. Listed on BSE: 543635 and NSE: PPLPHARMA.
Piramal Pharma reported revenue of ₹8,869.08 Cr for FY 2025-26 (down 3.1% YoY) based on consolidated financials.
Piramal Pharma has 10 current directors:
- Peter D Deyoung - Whole-Time Director
- Nandini Ajay Piramal - Whole-Time Director
- Vivek Valsaraj - Whole-Time Director
- Ramadorai Subramanian - Director
- Jairaj Manohar Purandare - Director
- Sridhar Gorthi - Director
- Peter Andrew Stevenson - Director
- Nathalie Ann Leitch - Director
- Vibha Paul Rishi - Director
- Amit Jain - Director
The latest financial statements of Piramal Pharma on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 July 2025. Year-wise statements from FY 2020 are in the company report.
The GSTIN of Piramal Pharma is 27AALCP0909M1Z1, registered in Maharashtra. The company has 19 GST registrations in all, of which 19 are active. Other active GSTINs include 27AALCP0909M2Z0 (Maharashtra), 36AALCP0909M1Z2 (Telangana), 23AALCP0909M1Z9 (Madhya Pradesh).
The CIN (Corporate Identification Number) of Piramal Pharma is L24297MH2020PLC338592. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Piramal Pharma is a listed company as per MCA records. Its shares are listed on both BSE (code: 543635) and NSE (symbol: PPLPHARMA).
Piramal Pharma has 64 court cases on record: 50 filed by the company and 14 filed against it. 32 are pending. Most are in the district courts.
Piramal Pharma was incorporated on 04 March 2020, making it 6+ years old. It is registered with the Registrar of Companies, Mumbai.
Piramal Pharma has 10 deals on record (5 market trades, 3 funding rounds, 1 rights issue), with disclosed funding of ₹4,300.42 Cr; the latest was in February 2025.
The peers of Piramal Pharma by revenue are Dow Chemical International Private Limited, Reckitt Benckiser (India) Private Limited, Gujarat State Fertilizers & Chemicals Limited, Divi's Laboratories Limited, Macleods Pharmaceuticals Ltd and 5 more, all in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Amit Jain was appointed as Director on 14 May 2025. Neeraj Bharadwaj ceased to be Director on 14 May 2025. Nathalie Ann Leitch was appointed as Director on 28 Jan 2025. Piramal Pharma has 14 board changes on record in total.